Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma

Wright, Chadwick; Maly, Joseph; Zhang, Jun; Knopp, Michael V.

doi:10.1016/j.cpet.2016.08.005

Cited by 14 publications

(9 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) is a reliable cancer outcome predictor [7,8] based on the prevalence of enhanced glucose uptake by human cancers. FDG-PET is increasingly used for the global assessment of lymphomas, allowing not only evaluation of tumour extensiveness and aggressiveness, but also quantification of their metabolic activity [9][10][11][12]. CHOP-R (a combination chemotherapy containing cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab) is currently the standard first line therapy for NHL patients [13].…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

Purpose Increased glycolytic activity with accumulation of extracellular lactate is regarded as a hallmark of cancer. In lymphomas, FDG-PET has undeniable diagnostic and prognostic value, corroborating that these tumours are avid for glucose. However, the role of glycolytic metabolism-related molecules in lymphoma is not well known. Here, we aimed to evaluate the clinical and prognostic significance of a panel of glycolytic metabolism-related molecules in primary non-Hodgkin lymphomas (NHL) and to test in vitro the putative therapeutic impact of lactate transport inhibition. Methods We assessed, by immunohistochemistry, the expression of the metabolism-related molecules MCT1, MCT2, MCT4, CD147, GLUT1, LDHA and CAIX in both tumour and stroma compartments of tissue sections obtained from 104 NHL patients. In addition, the lymphoma-derived cell lines OZ and DOHH-2 were used to evaluate the effect of AZD3965 on their viability and on apoptosis induction, as well as on extracellular lactate accumulation. Results We found that expression of MCT1 in the NHL tumour compartment was significantly associated with a poor clinicopathological profile. We also found that MCT4 and CAIX were present in the stromal compartment and correlated with an aggressive phenotype, while MCT1 was absent in this compartment. In addition, we found that AZD3965-mediated disruption of MCT1 activity led to inhibited NHL cell viability and extracellular lactate accumulation, while increasing apoptotic cell death.Conclusions Our results indicate that elevated glycolytic activity is associated with NHL aggressiveness, pointing at metabolic cooperation, mediated by MCT1 and MCT4, between tumour cells and their surrounding stroma. MCT1 may serve as a target to treat NHL (diffuse large B cell lymphoma) patients with high MCT1/low MCT4 expressing tumours. Further (pre-)clinical studies are required to allow the design of novel therapeutic strategies aimed at e.g. reprogramming the tumour microenvironment.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, dPET is poised to similarly embrace its ability to improve image reconstruction and visualization of more precisely detected annihilation events. This is a major area of opportunity to leverage dPET technology and therefore we have proposed refined nomenclature to characterize reconstructed PET images into standard definition (SD, matrix size ≤ 200), high definition (HD, matrix size > 200 but ≤ 400), and ultrahigh definition (UHD, matrix size > 400) [ 23 ]. Furthermore, HD and UHD image reconstruction utilizes PSF and Gaussian filtering as part of its overall optimization.…”

Section: Features Of Pet Systemsmentioning

confidence: 99%

“… Intraindividual comparison in a patient scanned on the cPET/CT (Gemini 64 ToF, Philips Healthcare, Cleveland, Ohio, USA) system and a precommercial release dPET/CT (Vereos, Philips Healthcare, Cleveland, Ohio, USA) system using different reconstruction matrix/voxel volume sizes with a 3D line-of-response TOF blob-based algorithm [ 5 , 17 , 22 , 23 ]. The patient was intravenously given a standard dose of 485 MBq of 18 F-FDG and then underwent imaging on the dPET/CT system at 50 min and the cPET/CT system at 76 min after injection.…”

Section: Figurementioning

confidence: 99%

Advanced Functional Tumor Imaging and Precision Nuclear Medicine Enabled by Digital PET Technologies

Wright

Binzel

Zhang

et al. 2017

Contrast Media & Molecular Imaging

Self Cite

View full text Add to dashboard Cite

The purpose of this article is to provide a brief overview of the background, basic principles, technological evolution, clinical capabilities, and future directions for functional tumor imaging as PET evolves from the conventional photomultiplier tube-based platform into a fully digital detector acquisition platform. The recent introduction of solid-state digital photon counting PET detector is the latest evolution of clinical PET which enables faster time-of-flight timing resolution that leads to more precise localization of the annihilation events and further contributes to reduction in partial volume and thus makes high definition and ultrahigh definition PET imaging feasible with current standard acquisition procedures. The technological advances of digital PET can be further leveraged by optimizing many of the acquisition and reconstruction methodologies to achieve faster image acquisition to improve cancer patient throughput, lower patient dose in accordance with ALARA, and improved quantitative accuracy to enable biomarker capability. Digital PET technology will advance molecular imaging capabilities beyond oncology and enable Precision Nuclear Medicine.

show abstract

“…Quanto à tendência futura dessa demanda, ela deve continuar em elevação [7][8][9]. Entretanto, os patamares de demanda por combustível nuclear para reatores de pesquisa não se alteram significativamente no período de um ano, que é o horizonte de planejamento mais comum para a indústria em geral [52,56,111].…”

Section: Considerações Sobre a Demandaunclassified

“…Em contrapartida, a partir da década de 1950 surgiu um novo ramo dentro do desenvolvimento da tecnologia nuclear, que foi a medicina nuclear [6,7].…”

Section: Introductionunclassified

Desenvolvimento de um modelo para dimensionamento da capacidade produtiva de fábricas de combustível nuclear para reatores de pesquisa

Negro¹

View full text Add to dashboard Cite

Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma

Cited by 14 publications

References 153 publications

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

Advanced Functional Tumor Imaging and Precision Nuclear Medicine Enabled by Digital PET Technologies

Desenvolvimento de um modelo para dimensionamento da capacidade produtiva de fábricas de combustível nuclear para reatores de pesquisa

Contact Info

Product

Resources

About